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AKAPIn most target tissues, the adenylyl cyclase/cAMP/PKA, the extracellular signal regulated kinase and the
protein kinase B/Akt are the main pathways employed by the type 2 corticotropin-releasing hormone
receptor to mediate the biological actions of urocortins (Ucns) and CRH. To decipher the molecular
determinants of CRH-R2 signaling, we studied the signaling pathways in HEK293 cells overexpressing
recombinant human CRH-R2β receptors. Use of speciﬁc kinase inhibitors showed that the CRH-R2β
cognate agonist, Ucn 2, activated extracellular signal regulated kinase in a phosphoinositide 3-kinase and
cyclic adenosine monophosphate/PKA-dependent manner with contribution from Epac activation. Ucn 2
also induced PKA-dependent association between AKAP250 and CRH-R2β that appeared to be necessary
for extracellular signal regulated kinase activation. PKB/Akt activation was also mediated via pertussis
toxin-sensitive G-proteins and PI3-K activation but did not require cAMP/PKA, Epac or protein kinase C for
optimal activation. Potential feedback mechanisms that target the CRH-R2β itself and modulate receptor
trafﬁcking and endocytosis were also investigated. Indeed, our results suggested that inhibition of either
PKA or extracellular signal regulated kinase pathway accelerates CRH-R2β endocytosis. Furthermore, Ucn
2-activated extracellular signal regulated kinase appeared to target β-arrestin1 and modulate, through
phosphorylation at Ser412, β-arrestin1 translocation to the plasma membrane and CRH-R2β internaliza-
tion kinetics. Loss of this “negative feedback” mechanism through inhibition of the extracellular signal
regulated kinase activity resulted in signiﬁcant attenuation of Ucn 2-induced cAMP response, whereas Akt
phosphorylation was not affected by altered receptor endocytosis. These ﬁndings reveal a complex
interplay between the signaling molecules that allow “ﬁne-tuning” of CRH-R2β functional responses and
regulate signal integration.+44 2476 574637.
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In mammals, the type 2 corticotropin-releasing hormone receptor
(CRH-R2) plays critical roles in central and peripheral homeostatic
mechanisms controlling energy balance [1–3] by controlling feeding
behavior as well as glucose utilization and insulin sensitivity in
skeletal muscle. In addition, CRH-R2 mediates important anxiolytic
effects in the brain as well as cardioprotection, tissue angiogenesis
and gastrointestinal regulatory effects at the periphery [4–7]. This
heptahelical G-protein coupled receptor (GPCR) is activated by the
family of CRH-related peptides, CRH and urocortins (Ucns), although
it preferentially binds Ucn rather than CRH [8].Similar to the closely related type 1 CRH-R (CRH-R1), the CRH-R2
can regulate diverse signaling pathways through activation of
multiple G-proteins [9]. Second messenger studies suggest that the
Gsα/adenylyl cyclase/cAMP, protein kinase B (PKB)/Akt and members
of the family of mitogen-activated protein kinases (MAPK) are key
signaling intermediates downstream of CRH-R2 activation important
for physiological functions of urocortins and CRH in target cells
[10–13]. The latter signaling pathway appears to involve multiple
G-proteins (Gq-, Gi- and Go-) and a number of signaling molecules
including, phosphatidylinositol-3 OH kinase (PI3-K), MAPK kinase 1,
phospholipase C, Raf-1 kinase, tyrosine kinases, and intracellular Ca2+
[14–16]. Interestingly, recent studies suggest that CRH-R2–MAPK
interactions appear to require exclusively G-protein dependent
pathways but not β-arrestin dependent pathways [17]. This is in
marked contrast to the CRH-R1, which utilizes both G-protein
dependent and -independent pathways to activate the MAPK
cascade [18]. Therefore, it appears that β-arrestin dependent CRH-R2
endocytosis is employed as a mechanism to terminate CRH-R2
receptor signaling rather than inducing a “second-wave” of intracel-
lular signals.
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regulate signal integration are unknown. Studies on other GPCRs
have demonstrated both synergistic and antagonistic actions of the
cAMP pathway on MAPK activation [19]. The cAMP-dependent kinase
PKA can modulate the functional activity of multiple intracellular
proteins involved in extracellular signal regulated kinase (ERK1/2)
signaling; for example in B-Raf negative cells, PKA-induced Rap1
activation leads to inhibition of Ras–Raf-1 interaction and ERK1/2
signaling. In contrast, in cells expressing B-Raf, PKA stimulates ERK1/
2 phosphorylation via sequential activation of Rap-1 and B-Raf. This
has important biological consequences and reﬂects the ability of
cAMP to inhibit proliferation in many cell types but stimulate
proliferation in others [19]. For some GPCRs, these cross-talk
mechanisms involve feedback mechanisms targeting the receptor
itself and regulating its signaling efﬁciency; for example, phosphor-
ylation by PKA of the β2-adrenergic receptor switches its coupling
from Gs to Gi leading to stimulation of the ERK1/2 signaling pathway
[20], whereas a similar PKA action on CRH-R1 at Ser301 of the 3rd
intracellular loop (IC3) attenuates receptor/Gq-protein coupling and
ERK1/2 phosphorylation [21]. In addition to regulation of receptor-G-
protein association, PKA can inﬂuence signaling potency of some
GPCRs by either promoting or inhibiting receptor internalization
[22,23] and thus modifying the amount of receptors expressed in the
plasma membrane available for ligand binding and activation. PKA is
not the only component of the cAMP/PKA pathway involved in
the regulation of GPCRs signaling efﬁciency; A-kinase anchoring
proteins (AKAPs) by association with speciﬁc GPCRs provide multi-
valent docking platforms for PKA, PKC, and other signaling regulators
to inﬂuence spatial resolution and localization of downstream sig-
naling events [24]. The presence of speciﬁc AKAP subtypes is crucial
for propagation of ERK1/2 signal. Furthermore, MAPK, in particular
ERK1/2, can inhibit GRK and β-arrestin-dependent receptor
desensitization and internalization by phosphorylating β-arrestin1
at Ser-412 and GRK2 to a carboxyl-terminal serine residue (Ser-670)
[25,26].
In the present study we used recombinant CRH-R2β stably
expressed in HEK293 cells and speciﬁc kinase inhibitors to investigate
signaling characteristics as well as potential interactions between the
Ucn2 activated cAMP/PKA/AKAP and ERK1/2 cascades and the
presence of feedback mechanisms regulating homologous CRH-R2β
endocytosis.
2. Materials and methods
2.1. Materials
Ucn2 was purchased from Bachem UK Ltd (Helens, Merseyside,
UK). Radiodinated rat [tyr°]Ucn1 was obtained from Amersham
(GE Healthcare UK Ltd, Buckinghamshire England). Myristoylated
PKA inhibitor, U0126 (MEK inhibitor) and forskolin were from
Calbiochem/Merck Biosciences (Nottingham, UK). AKAP250 and
CRH-R1/2 antibodies were from Santa Cruz Biotechnology (Santa
Cruz, California, USA). Phospho-ERK1/2 (Thr202/Tyr204), total ERK1/2,
and phospho-β-arrestin-1 (Ser 412) were from Cell Signaling
(Chandlers Ford, Hampshire, UK); pan-arrestin and total β-arrestin-1
antibodies were from Abcam (Cambridge, UK). Secondary antibodies
Alexa Fluor®405, Alexa Fluor®488, Alexa Fluor®594, Alexa Fluor®680
and gold slowfade mounting solution with DAPI were purchased from
Invitorgen/Molecular Probes (Paisley, UK), and IRDye 800-conjugated
goat antirabbit IgG was from Rockland Immunochemicals (Gilberts-
ville, PA, USA). VECTASHIELD Mounting Medium without DAPI was
from Vector Laboratories, Inc. (Orton Southgate, Peterborough, UK).
Cell culture media, gentamicin (G-418), Lipofectamine 2000,
pcDNA3.1(+), restriction enzymes and Pfu polymerase were from
Gibco/Invitrogen (Paisley, UK). dNTPs and DNA ladder were pur-
chased from Bioline Ltd (London, UK). Primers were purchased fromTANG (Gateshead, UK). All other chemicals were purchased from
Sigma Aldrich Company Ltd (Gillingham, UK).
2.2. Transfection of CRH-R2β to HEK293 cells
Human CRH-R2β cDNAs subcloned in pcDNA3.1(+) (10 μg) were
transfected in HEK293 cells using Lipofectamine 2000 reagent,
according to the manufacturer's protocol. After 3 days of non-
selective growth in normal growth media, followed by 15 days of
growth in media containing 500 μg/ml gentamicin (G418, Gibco),
clones were selected by serial dilution of surviving foci and
maintained in 250 μg/ml gentamicin. The optimal concentration of
gentamicin and the length of cell growth was determined by growing
non-transfected HEK293 cells in media containing different concen-
trations of the antibiotic (50–1000 μg/ml) for 21 days and performing
a cell viability MTT (thioazolyl blue) assay. After 2 months the
expression of CRH-R2β was veriﬁed by RT–PCR, immunoblotting,
confocal microscopy analysis, and functional assays (including cAMP
production and ERK activation). At least two clones were selected and
used for further studies. HEK293 cells stably expressing recombinant
CRH-R2β (293-R2β) were maintained in high-glucose DMEM with
Glutamax containing 10% FCS, 100 U/ml penicillin and 100 μg/ml
streptomycin and 250 μg/ml gentamicin.
2.3. Transfection of β-arrestin1 siRNA to 293-R2β
Beta-arrestin 1 siRNA was purchased from QIAGEN (West Sussex,
UK). AllStars negative siRNA with a 3′-AlexaFluor-488 modiﬁcation
(QIAGEN) was used as a control. One day before transfection 293-R2β
were plated in 6-well plates in normal growth media without any
antibiotics. Lipofectamine 2000 was used for the delivery of 1 nmol
siRNA into cells according to manufacturer's instructions. Subsequent
experiments were performed 48 h after transfections as previously
described [17].
2.4. Receptor second messenger studies and Western blotting
Cells were grown in 12-well plates and when reached 70–80%
conﬂuency, media was aspirated and the cells were washed with
plain DMEM. Following pre-treatment with inhibitor (U0126 10 μM)
for 1 h, stimulation buffer (DMEM containing 10 mM MgCl2 and
0.1 mg/ml 3-isobutyl-1-methylxanthine-IBMX) was added on the
cells for 20 min at 37 °C and then cells were washed with plain
DMEM and stimulated with 1–100 nM Ucn2, CRH or 10 μM forskolin
for 15 min. The reaction was stopped by adding 10 μl of concentrated
HCl for 15–20 min and cells were transferred in 1.5 ml tubes. After a
brief spin, the cells and media were stored at −20 °C. The cAMP
levels were determined by commercially available ELISA Direct
Cyclic AMP Enzyme Immunoassay Kit (Assay Designs Ins., Ann
Arbor, MI, USA).
For MAPK phosphorylation assays, appropriate inhibitors were
added for 30 min (1 μM myr-PKAi, 10 μM SQ22356, 10 μM st-Ht-31,
50 μM LY-294002, 100 μM brefeldin A) followed by stimulation of
cells with 100 nM Ucn2 for various time periods (2–60 min). At the
end of the stimulation period, media was removed and cells were
brieﬂy washed with ice-cold PBS and then were lysed by addition of
150 μl of 2× SDS–PAGE sample buffer (Sigma Aldrich Ltd). Solubilized
material was collected, sonicated for 20 sec and boiled for further
5 min. After a brief centrifugation step (2000g for 30 s), protein
lysates were stored at −20 °C until used. Before electrophoresis,
protein extracts were centrifuged at 3000g for 5 min to remove
insoluble material and 15 μl of the supernatant were loaded on 10%
SDS–PAGE gels. For β-arrestin1 phosphorylation studies, cells were
lysed in 100 μl of RIPA buffer containing protease and phosphatase
inhibitors cocktail (Santa Cruz, CA, USA). Protein concentration was
determined with BCA™ Protein Assay Kit (Pierce, Rockford, IL, USA),
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at 200 V for approximately 1 h. Proteins were electrophoretically
transferred to PVDF membrane at 100 V for 1 h. After completion of
transfer, the PVDF membrane was incubated with 8–10 ml Licor
blocking buffer (LI-COR Biosciences, Cambridge, UK) for 1 h at room
temperature with gentle agitation. To determine ERK1/2 phosphor-
ylation the membrane was incubated simultaneously with the
phospho-ERK1/2 (Thr202/Tyr204) antibody and total ERK2 antibody
(dilutions 1:1500 and 1:2000, respectively) in 10 ml of Licor blocking
buffer with gentle agitation overnight at room temperature. For
β-arrestin1 phosphorylation, membranes were incubated simulta-
neously with phospho-β-arrestin1 (Ser412) and total β-arrestin1
antibodies (dilutions 1:500 and 1:1000, respectively) in 10 ml of
Licor blocking buffer with gentle agitation overnight at 4 °C. After
18 h, the antiserum was removed and the membrane was washed
3×10 min with 15 ml TBS-T (TBS-0.1% Tween), before addition of
secondary antibody conjugated to a ﬂuorescent entity: IRDye™800-
conjugated goat antirabbit IgG and/or Alexa Fluor®680-conjugated
goat antimouse IgG (dilution 1:6000) in 10 ml of Licor blocking buffer
with gentle agitation for 1 h at room temperature. At the end of the
incubation period, membranes were washed twice with 15 ml of
TBS-T and once with 15 ml of TBS. The membrane was dried,
visualized and analyzed on the Odyssey Infrared Imaging System
(LI-COR Biosciences, Cambridge, UK).
In some experiments PVDF membranes were treated with an
alkaline phosphatase containing solution. The membrane was
incubated at 37 °C overnight in 10 ml of alkaline phosphatase
buffer and 1000 U of alkaline phosphatase. The following morning
membrane was washed with TBS-T and incubated with the
phospho-β-arrestin1 (Ser412) and total β-arrestin1 antibodies as
described above. To monitor Akt phosphorylation, membranes wereFig. 1. Effect of CRH-R2 speciﬁc antagonists (a) and signaling molecules inhibition on ERK1
carried out in the presence or absence of anti-sauvagine 30 (1 mM) (a) or after pre-treatme
brefeldin A (BFA-100 μM) for 30 min (b–c). In some experiments (c) cells with treated with U
treated with or without myr-PKAi were stimulated with Ucn2 (100 nM) for various time po
Following cell lysis and centrifugation, supernatants were subjected to SDS–PAGE and immun
to determine the phosphorylated/activated ERK1/2 and secondary antibodies conjugated
[near-infrared (IR) ﬂuorophore dyes] as described in Materials and methods. Top panels ar
three independent experiments. Data analysis was carried out by using one-way ANOVA an
(i.e., no antagonist or inhibitor pre-treatment; *Pb0.05).incubated with the phospho-Akt antibody (Ser473) (1:1000 in Licor
buffer) with gentle agitation overnight at 4 °C. Following 3 washes
with TBS-T, goat antimouse Alexa®Fluor 680 conjugated IgG
(dilution 1:6000 in 10 ml of blocking buffer) was added for 1 h at
room temperature, before visualization and analysis by the Odyssey
Infrared Imaging System (LI-COR Biosciences, Cambridge, UK).
Membranes were then stripped with 25 mM glycine buffer pH 2
containing 2% SDS and re-probed with total Akt antibody (dilution
1:500 in Licor blocking buffer) with gentle agitation overnight at
room temperature.2.5. Plasma membrane fractionation and β-arrestin immunoblotting
For plasma membrane fractionation, 293-R2β were grown in
10 cm Petri dishes, and when reached 80% conﬂuency, cells were
deprived from FCS for 1 h before treatment with 100 nM Ucn2 or CRH
for the indicated time intervals. Membrane proteins were prepared
using ProteoExtract® Native Membrane Protein Extraction Kit (Cal-
biochem/ Merck Biosciences, Nottingham, UK). Protein concentration
was determined using a BCA™ Protein Assay Kit (Pierce, Rockford, IL,
USA). Protein fractions (5 μg) were analyzed by Western blot analysis.
Following SDS–PAGE and electrophoretic transfer, membranes were
incubated overnight at 4 °C with pan-arrestin antibody (recognizes
both arrestins β-arrestin1 of 49 kDa and β-arrestin2 of 47 kDa)
(dilution 1:500), after a 1 h incubation step in TBS-T containing 5%
BSA at room temperature. Following incubation with the secondary
horseradish peroxidase-conjugated antirabbit IgG (DAKO UK Ltd, Ely,
UK) (1:2000 dilution in TBS-T for 1 h at room temperature), proteins
were visualized using ECL reagent from Amersham/Pharmacia
Biotech (GE Healthcare UK Ltd, Little Chalfont, UK)./2 activation by Ucn2 in 293-R2β cells. Stimulation with Ucn2 (100 nM) for 5 min was
nt of cells with or without LY-294002 (50 μM), myr-PKAi (1 μM), SQ22356 (10 μM) or
cn2 (100 nM) and 8-CPT-2′-O-Me-cAMP (10 μM) for 5 min. Alternatively (d) cells pre-
ints (0–10 min) to determine the temporal proﬁle of Ucn2 induced ERK1/2 activation.
oblotted with primary antibodies for phospho-ERK1/2 (Thr204/Tyr202) and total-ERK2
to IRDye™ 800 (goat antirabbit IgG) and Alexa Fluor® 680 (goat antimouse IgG)
e representative Western blots. Data represent the mean±SEM of 3 estimations from
d Dunnett's test to compare mean values between the treatment groups and controls
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Plasma membrane-rich fractions were prepared from 293-R2β as
described above. Stimulated cells were then rinsed twice with ice-
cold PBS and lysates were then incubated overnight at 4 °C with
antibodies speciﬁc for CRH-R1/2 (Santa Cruz Biotechnology, Santa
Cruz, California, USA) and protein A/G agarose (Pierce, Rockford, IL
USA). The immunoprecipitates were collected, washed four times PBS
before being resuspended in Laemmli sample buffer. After heating at
95 °C for 5 min, the samples were centrifuged brieﬂy and the
supernatants analyzed by SDS–PAGE on 10% gels. Following electro-
phoretic transfer, membranes were incubated overnight at 4 °C with
pan-arrestin antibody (dilution 1:500) or AKAP250 (dilution 1:500).
Membrane fractions were also incubated with pan-cadherin (dilution
1:500 in TBS-T) or GAPDH (1:60,000 in TBS-T) after a 1 h incubation
step in TBS-T containing 5% BSA at room temperature. Following
incubation with the secondary horseradish peroxidase-conjugated
antirabbit IgG (DAKOUK Ltd, Ely, UK) (1:2000 dilution in TBS-T for 1 h
at room temperature), proteins were visualized using ECL reagent
from Amersham/Pharmacia Biotech (GE Healthcare UK Ltd, Little
Chalfont, UK).
2.7. Immunoﬂuorescent confocal microscopy and internalization studies
Cells were seeded on coverslips coated with 100 μg/ml poly-D-
lysine in PBS. When reached 70–80% conﬂuency, the cells were
treated with various concentration of agonists and ﬁxed with 4% PFA.
Non-speciﬁc binding was blocked with 1% BSA in PBS-Triton X-100
(0.01%) for 1 h at room temperature. Following a 5 min wash with
PBS, a PBS solution containing 1:50 monoclonal mouse antibodyFig. 2. AKAPs and CRH-R2β signaling. (a) Cells were pretreated with or without Ht-31 (1
determined as described in Materials and methods. Data represent the mean±SEM of 3 es
inhibitor pretreatment. (b) Top panel: RT–PCR of AKAP250 (gravin) mRNA present in untran
ampliﬁed DNA fragment was 300 bp. Bottom panel: Cell lysates from 293-R2β cells were
antibody in the presence or absence of blocking peptide as described inMaterials andmethod
Ucn2 on AKAP250 subcellular distribution was monitored by indirect ﬂuorescence confo
distribution was monitored by using speciﬁc primary antibodies for AKAP250 and Alexa-Fluo
experiments. In addition (d), 293-R2β cells were pretreated with or without myr-PKAi, LY o
Subsequently, membrane-rich fractions were prepared, solubilized and immunoprecipitated
by immunoblotting with AKAP250 antibodies to identify potential complex formation.
independent experiments.against AKAP250 was added for overnight incubation at 4 °C.
Alternatively, slides were incubated with polyclonal goat antibody
against the C-terminus of CRH-R1/2 (1:100 in PBS) for 2 h at room
temperature. At the end of the incubation period, the primary
antibody was removed and following three PBS washes for 5 min
each, donkey anti-rabbit AlexaFluor®488 or donkey anti-goat Alexa-
Fluor®594 were added in 1:400 dilution each for 1 h at room
temperature. After three ﬁnal washes with PBS, slides were mounted
with VECTASHIELD Mounting Medium with DAPI after three ﬁnal
washes with PBS. The slides were examined under an oil immersion
objective (×63) using a Leica model DMRE laser scanning confocal
microscope (LeicaMicrosystems, UK, Buckinghamshire, Milton, Keynes,
UK) with TCS SP2 scan head. Laser 543 nm at 50% of power and
emission ﬁlter set at 555–620 nm were used to examine Alexa-
Fluor®594 staining, and Laser 488 nm at 30% of power and emission
ﬁlter set at 500–535 nm was used to examine AlexaFluor®488
staining. DAPI or AlexaFluor®405 staining was examined with Laser
405 at 10% of power and emission ﬁlter set at 410–450 nm. The scan
speed was set at 400 Hz, and the format was 1024×1024 pixels.
Optical sections (0.5 μm) were taken, and representative sections
corresponding to the middle of the cells are presented. After indirect
immunoﬂuorescent staining, no speciﬁc ﬂuorescence was observed in
cells treated with secondary antibody only or when blocking peptide
was incubated with the primary antibody prior to incubation on cells.
For each treatment, between 20 and 30 individual cells in ﬁve random
ﬁelds of view were randomly selected and examined. Fluorescence
intensity proﬁles were generated along multiple line axes, analyzed,
and quantiﬁed using ImageJ software developed at the National
Institutes of Health (http://rsb.info.nih.gov/ij/). Relative quantiﬁcation
of intracellular (internalized) receptor was carried out by measuring0 μM) prior to stimulation with Ucn2 (100 nM) for 5 min. Activation of ERK1/2 was
timations from three independent experiments. *Pb0.05 compared with cells without
sfected HEK293 or 293-R2β cells using speciﬁc oligonucleotide primers. The size of the
fractionated on SDS–PAGE and subjected to immunoblotting with a speciﬁc AKAP250
s. Identical results were obtained from three independent experiments. (c) The effect of
cal microscopy. Cells were stimulated with Ucn2 (100 nM) for 5 min and AKAP250
r® 488 secondary antibody (green). Identical results were obtained from 4 independent
r bisindolylmaleimide II, for 30 min prior to stimulation with Ucn2 (100 nM) for 5 min.
with speciﬁc CRH-R1/2 antibodies. Proteins were resolved on SDS–PAGE gels, followed
Representative immunoblots are presented. Identical results were obtained from 4
900 D. Markovic et al. / Biochimica et Biophysica Acta 1813 (2011) 896–907the amount of total ﬂuorescence along the longitudinal axis
corresponding to the intracellular space (average 4–18 μm).
2.8. Statistics
The results obtained are presented as the mean±SEM of each
measurement. Statistical analysis was carried out using SPSS 18
software. Datawere tested for homogeneity, and comparison between
group means was performed by one-way analysis of variance and
Dunnett's test. Probability values of Pb0.05 were considered to be
signiﬁcant.
3. Results
3.1. Role of cAMP/PKA/AKAPs pathway and PI3-K on Ucn2-induced
ERK1/2 activation
Our previous studies [14,17] demonstrated that treatment of
HEK293 cells stably expressing CRH-R2β receptor (293-R2β) with
either Ucn1 or Ucn2 (100 nM) signiﬁcantly increased intracellular
cAMP levels as well as ERK1/2. These ﬁndings were conﬁrmed in the
present study; we also showed that the speciﬁc CRH-R2 receptor
antagonist anti-sauvagine 30 (1 μM)was able to block the stimulatory
action of 100 nM Ucn2 on ERK1/2 signaling, demonstrating the
speciﬁcity of Ucn2 actions (Fig. 1a).
The role of phosphatidylinositol-3 OH kinase (PI3-K), a signaling
molecule previously shown to be involved in CRH-R1α and CRH-R2β
ERK1/2 interactions [15,18], on CRH-R2β mediated ERK1/2 phos-
phorylation, was also investigated, by using the speciﬁc PI3-K
inhibitor LY-294002. Pre-treatment of 293-R2β cells with 50 mM
LY-294002 for 30 min, signiﬁcantly impaired by 60±5% Ucn2
(100 nM)-induced ERK1/2 (Fig. 1b). Moreover, a potential role for
cAMP/PKA pathway in Ucn2 induced ERK1/2 activation was also
investigated. For this purpose, 293-R2β cells were treated with
adenylyl cyclase and PKA inhibitors (SQ22356 and myr-PKAi,Fig. 3. Signaling characteristics of Akt activation by Ucn2 in 293-R2β cells. (a) Cells pretreate
for 5 min. Following cell lysis and centrifugation, supernatants were subjected to SDS–PAGE
determine the phosphorylated/activated Akt and secondary antibodies conjugated to IRDye
(IR) ﬂuorophore dyes] as described in Materials and methods. Top panels are representativ
bisindolylmaleimide II or brefeldin A before Ucn2 stimulation for 5 min and determination o
toxin (PTX) (12 h, 100 ng/ml) before stimulation with Ucn2 (100 nM) for 5 min. Data represe
was carried out by using one-way ANOVA and Dunnett's test to compare mean values b
*Pb0.05).respectively) and ERK1/2 phosphorylation after stimulation with
100 nM Ucn2 for 5 min was determined. Results demonstrated that
both inhibitors signiﬁcantly impaired (by 40% and 50%, respectively)
Ucn2 induced ERK1/2 phosphorylation (Fig. 1c). We also examined
the potential involvement of PKA-independent pathways down-
stream of cAMP mediating Ucn2-induced ERK1/2 activation, and
speciﬁcally the role of Epac, a guanine nucleotide exchange factor for
the small GTPases Rap1 and Rap2. Epac signaling in the pituitary, locus
ceruleus and heart has been implicated in CRH and Ucn1 activation of
ERK1/2 [27–29]. In the 293-R2β cells, 8-CPT-2′-O-Me-cAMP (a
selective activator of Epac) did not alter basal conditions; however,
it increased Ucn2 (100 nM)-activated ERK1/2 phosphorylation by 30%
(Fig. 1c). Pre-incubation of cells with brefeldin A, an Epac antagonist,
exerted a signiﬁcant inhibitory effect by 25% on Ucn2-induced
maximal ERK1/2 activation at 5 min (Fig. 1c). Previous studies on
Ucn2 activated ERK1/2 phosphorylation identiﬁed a transient re-
sponse, which was maximal within 5 min of treatment and returned
to basal levels after 30 min of agonist stimulation [17]. Interestingly,
pre-treatment of 293-R2β cells with myr-PKAi attenuated by 60%
Ucn2 (100 nM) induced ERK1/2 activation at 5–10 min only, whereas
ERK1/2 early activation (within 2 min) was increased by 20–30%
(Fig. 1d).
The involvement of signaling molecules downstream of cAMP/PKA
such as AKAPs, on Ucn2-induced ERK1/2 activation was also
investigated by using Ht-31 to interrupt PKA binding to AKAPs [30].
Results (Fig. 2a) showed that pre-treatment of 293-R2β cells with Ht-
31 (10 μM) for 30 min markedly reduced (44±6%) ERK1/2 phos-
phorylation induced by 100 nM Ucn2. Several types of AKAPs are
expressed in mammalian cells [31]; of particular interest in GPCR
signaling is AKAP250 (gravin), an adaptor protein important for
agonist-induced GPCR internalization and recycling. Using RT–PCR
and immunoblotting of cell lysates using speciﬁc antibodies, we
showed that gravin mRNA and protein is expressed in 293-R2β cells
(Fig. 2b) in agreement with previous reports [32]. Detection of gravin
subcellular localization by indirect immunoﬂuorescence confocald with or without LY-294002 (50 μM for 30 min) were stimulated with Ucn2 (100 nM)
and immunoblotted with primary antibodies for phospho-Akt (Ser473) and total-Akt to
™ 800 (goat antirabbit IgG) and Alexa Fluor® 680 (goat antimouse IgG) [near-infrared
e Western blots. Alternatively (b) cells were pre-treated with or without myr-PKAi, or
f phospho-Akt. In some experiments (c), cells were pretreated with or without pertussis
nt themean±SEM of 3 estimations from three independent experiments. Data analysis
etween the treatment groups and controls (i.e. cells without inhibitor pretreatment;
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led to a rapid translocation (within 5 min) of gravin to the plasma
membrane (Fig. 2c). Co-immunoprecipitation studies showed that
recruited gravin to the plasma membrane in response to CRH-R2β
activation was associated with CRH-R2β receptor (Fig. 2d). This effect
was PKA-dependent since inhibition of PKA with myr-PKAi blocked
Ucn2-induced CRH-R2β-gravin binary complex formation. In contrast,
inhibition of PKC or PI3-K had no effect on CRH-R2β-gravin
association.3.2. Signaling molecules involved in Ucn2-induced Akt activation
In addition to cAMP and ERK1/2, treatment of 293-R2β cells with
Ucn2 (100 nM) for 5 min signiﬁcantly induced by 5 fold Akt
phosphorylation at Ser473 (Fig. 3a). Pre-treatment of cells with LY-
294002 signiﬁcantly impaired Ucn2 effect by 80%, identifying PI3-K as
the major signaling molecule upstream of Akt. The potential role of
cAMP/PKA and Epac pathways in Ucn2 induced Akt activation was
also investigated; treatment of 293-R2β cells with myr-PKAi or
brefeldin A had no effect on Ucn2-induced Akt phosphorylation
(Fig. 3b). Similar results were obtained with bisindolylmaleimide II
(100 nM), thus excluding the involvement of PKC in Akt activation
(data not shown). By pre-treating cells with pertussis toxin (PTX)
(12 h, ﬁnal concentration, 100 ng/ml), we evaluated the possible
involvement of Gi/Go proteins, downstream of CRH-R2β receptor inFig. 4. Effect of PKA inhibition on Ucn2-stimulated CRH-R2β endocytosis. Cells were pre-trea
Ucn2 (100 nM) for various time intervals (0–15 min). (a) Subsequent CRH-R2β internaliza
antibodies and Alexa-Fluor 594 secondary antibody for CRH-R2 (red). For quantiﬁcation of c
examined, and proﬁles of ﬂuorescence intensity, generated. The sum of ﬂuorescence intensity
Image J software. Results are expressed as the mean±SEM of three estimations from 20 indi
membrane-rich fractions were prepared and following SDS–PAGE, they were immunoblotte
to quantify agonist-induced loss of receptor expression from the cell membrane. Identical
mean±SEM of three estimations from two individual experiments. Data analysis was carri
basal (time 0) vs Ucn2 stimulated (time 15 min) groups (*Pb0.05) or between treatmentthe activation of the PI3-K–Akt pathway. Results showed that PTX
treatment abolished Ucn2-induced Akt activation, (Fig. 3c) conﬁrm-
ing that Gi/Go proteins are crucial for Akt phosphorylation at Ser473.3.3. Regulation of CRH-R2β internalization by the cAMP/PKA and ERK1/2
pathways
The demonstration of functional interactions between the cAMP
and ERK1/2 signaling cascades led us to investigate whether these
signals target the CRH-R2β receptor itself and modulate Ucn2
signaling potency through alteration in receptor internalization
kinetics. Our previous studies characterizing the temporal properties
of CRH-R2β internalization showed that substantial receptor inter-
nalization were evident after 30 min of Ucn2 treatment although
some receptor trafﬁcking in the cytoplasm was observed within
15 min of treatment [17]. Moreover, a functional role for the amino
acid cassette TAAV at the end of the receptor C terminus was
identiﬁed since loss of a potential phospho-acceptor site in mutant
receptors containing deletion or Ala substitution of the cassette TAAV
resulted in reduced ERK1/2 activation and accelerated receptor
internalization.
To investigate potential effects of PKA on CRH-R2β internalization
293-R2β cells were pre-treated with myr-PKAi and CRH-R2β
endocytosis was monitored by confocal microscopy. Results showed
that in myr-PKAi pre-treated cells Ucn2 (100 nM) for 15 min elicitedted with or without myr-PKAi for 30 min to inhibit PKA activity, before stimulation with
tion was monitored by indirect ﬂuorescent confocal microscopy using speciﬁc primary
ytoplasmic CRH-R2β distribution, 20 individual cells in ﬁve random ﬁelds of view were
of cytoplasmic (distance 4–18 μm) ﬂuorescence along the lines was measured by using
vidual cells. *Pb0.05 compared with control (no inhibitor) values. (b) Alternatively, cell
d with antibodies against CRH-R1/2 C-terminus. Densitometry scanning was carried out
results were obtained from 4 independent experiments. Results are expressed as the
ed out by using one-way ANOVA and Dunnett's test to compare mean values between
groups and controls (i.e., cells without inhibitor pretreatment; +Pb0.05).
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creased compared to control cells (Fig. 4a). Quantiﬁcation of red
ﬂuorescence in the intracellular space of 20 individual cells that were
randomly selected showed 30–40% increased amount of red ﬂuores-
cent signal throughout the intracellular space (4–18 mm) (indicative
of receptor internalization), in myr-PKAi pre-treated cells compared
to control (Fig. 4a), suggesting that PKA inhibition was associated
with increased receptor internalization. Cell membrane-rich fractions
were also prepared from cells pre-treated with or without myr-PKAi,
before treatment with Ucn2 (100 nM) for 15 min. CRH-R2β proteins
were detected as a single immunoreactive protein with an apparent
molecular mass of approximately 60 kDa, by Western blotting using a
speciﬁc antibody raised against the CRH-R1/2 C-terminus. Densito-
metric analysis revealed that PKA inhibition signiﬁcantly increased by
24% Ucn2 induced (15 min) loss of receptors expressed in the cell
membrane compared to untreated (control) cells (Fig. 4b), thus
conﬁrming the ﬁndings of the indirect ﬂuorescence confocal micros-
copy. In the last set of experiments, the purity of the membrane-rich
fractions and equal protein loading was conﬁrmed by immunoblot-Fig. 5. Regulation of CRH-R2β internalization by ERK1/2 in 293-R2β cells. Cells were pre-trea
activation (inset), before stimulation with Ucn2 (100 nM) for various time intervals (0–30 m
indirect ﬂuorescent confocal microscopy using speciﬁc primary antibodies and Alexa-Fluor 5
distribution following 15 min of agonist stimulation, 20 individual cells in ﬁve random ﬁeld
ﬂuorescence intensity of cytoplasmic (distance 4–18 μm) ﬂuorescence along the lines was m
estimations from 20 individual cells. Data analysis was carried out by using one-way ANOVA
(i.e., cells without inhibitor pretreatment; *Pb0.05). Alternatively, (b) cell membrane-rich frac
against CRH-R1/2 C-terminus. Densitometry scanning was carried out to quantify agonist-ind
from 4 independent experiments. Results are expressed as the mean±SEM of three estimat
ANOVA and Dunnett's test to compare mean values between basal (time 0) vs Ucn2 stimulat
without inhibitor pretreatment; +Pb0.05).ting; results showed that all samples contained equal amounts of the
plasma membrane protein cadherin whereas GAPDH, a cytosolic
protein, was not detected in any of the samples (data not shown).
Interestingly, disruption of PKA–AKAP interactions by incubationwith
Ht-31 also accelerated Ucn2-induced receptor internalization at
15 min was by 20–30%, highlighting the important role of AKAPs in
agonist-induced CRH-R2β trafﬁcking. In contrast, pretreatment of
cells with BFA did not alter Ucn2-induced CRH-R2β internalization
rate excluding Epac as a mediator of Ucn2-dependent CRH-R2β
internalization and effects on receptor internalization machinery
(data not shown).
Since PKA is involved in ERK1/2 activation, we next examined
whether PKA modulates CRH-R2β trafﬁcking indirectly through
activation of ERK1/2. Similar to the studies described before, confocal
microscopy was used to determine the effect of ERK1/2 in CRH-R2β
internalization in 293-R2β cells where ERK1/2 activation was blocked
by U0126. Preliminary experiments conﬁrmed that Ucn2 ERK1/2
interaction is MEK dependent (Fig. 5, inset) since U0126 pre-
treatment blocked Ucn2 induced ERK1/2 activation. In U0126 pre-ted with or without U0126 (10 μM) for 2 h to inhibit basal and Ucn2-dependent ERK1/2
in). The effect of U0126 on Ucn2 induced CRH-R2β internalization was monitored by
94 secondary antibody for CRH-R2 (red). (a) For quantiﬁcation of cytoplasmic CRH-R2β
s of view were examined, and proﬁles of ﬂuorescence intensity, generated. The sum of
easured by using Image J software. Results are expressed as the mean±SEM of three
and Dunnett's test to compare mean values between the treatment groups and controls
tions were prepared and following SDS–PAGE, they were immunoblotted with antibodies
uced loss of receptor expression from the cell membrane. Identical results were obtained
ions from two individual experiments. Data analysis was carried out by using one-way
ed (time 15 min) groups (*Pb0.05) or between treatment groups and controls (i.e., cells
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amount of red ﬂuorescent signal throughout the intracellular space
(4–18 mm) compared to control (Fig. 6a), suggesting that in
conditions of ERK1/2 inhibition, receptor internalization is increased.
No signiﬁcant difference in intracellular ﬂuorescent signal between
control and U0126-treated cells was detected after 30 min of Ucn2
treatment. Furthermore immunoblotting experiments (Fig. 5b)
showed that, in U0126-treated cells, Ucn2 was substantially more
potent in attenuating cell membrane receptor expression, indicative
of enhanced receptor internalization. Simultaneous inhibition of PKA
and ERK1/2 (by myr-PKAi and U0126, respectively) did not exert an
additional effect pointing towards the presence of a single pathway
simultaneously involving PKA and ERK1/2 rather than two distinct
independent cascades (data not shown).
3.4. Ucn2 induced ERK1/2 activation and phosphorylation of β-arrestin1
and feedback regulation of Ucn2-induced cAMP and Akt pathways
Previous studies have shown that ERK1/2 can potentially regulate
GPCR endocytosis through a mechanism involving phosphorylation
of β-arrestin1 at Ser412 [33]. Since our studies [17] implicated
β-arrestin1 in CRH-R2β desensitization and internalization, we
investigated whether β-arrestin1 is phosphorylated downstream of
Ucn2-activated ERK1/2 and this signaling event is important for
CRH-R2β internalization. The phosphorylation status of β-arrestin1
in 293-R2β cells was determined by immunoblotting using phospho-
β-arrestin1 (Ser412) speciﬁc antibodies. The speciﬁcity of thisFig. 6. Regulation of β-arrestin1 phosphorylation, membrane translocation and interactio
Cell lysates were fractionated by SDS–PAGE and following protein transfer in PVDF mem
and the Odyssey Infrared Imaging System. Membranes were also incubated in alkaline p
immunoreactivity. (a–b) β-arrestin1 phosphorylation, membrane translocation: Cells were
(100 nM) for various time intervals (0–10 min). Following cell lysis in RIPA buffer,
Fluor®680-conjugated goat antimouse IgG using the Odyssey Infrared Imaging System (a
PAGE, they were immunoblotted with antibodies against β-arrestin1 and IRDye™800-c
formation by co-immunoprecipitation: 293-R2β cells were pre-treated with or without
solubilization of membrane-rich fractions and immunoprecipitation with speciﬁc CRH-R1/
with either β-arrestin1 (top panel), phospho-β-arr1 (Ser412) (top panel far right)
Representative immunoblots are presented. Identical results were obtained from 4 indep
independent experiments. Data analysis was carried out by using one-way ANOVA and
(i.e., cells without inhibitor pretreatment; *Pb0.05).antibody in recognizing phospho-β-arrestin1 was established in
preliminary experiments (Fig. 6, inset): in total cell lysates prepared
from resting 293-R2β cells, phospho-β-arrestin1 was detected as a
single immunoreactive protein with an apparent molecular mass of
approximately 50 kDa. When PVDF membranes were incubated
overnight with a solution containing alkaline phosphatase, no
immunoreactive band was detected although β-arrestin1 was
detected by a speciﬁc β-arrestin1 antibody. Furthermore, phospho-
β-arrestin1 immunoreactivity was absent in 293-R2β cells trans-
fected with speciﬁc siRNA sequences that resulted in depletion of
β-arrestin1 [17]. These results conﬁrmed the speciﬁcity of the
antibodies used to detect phospho-β-arrestin1.
Results showed that under basal (non-stimulated) conditions
there were low levels of constitutively phosphorylated β-arrestin1
present in total cell lysates. Ucn2 treatment elicited a signiﬁcant
increase of phospho-β-arrestin1 immunoreactivity by 40% within
2 min (Fig. 6a); and after 10 min of Ucn2 treatment, phosphorylation
of β-arrestin1 at Ser412 was reduced by 45–50% below basal levels.
Ucn2 induced phosphorylation of β-arrestin1 appeared to be
regulated by ERK1/2 since in U0126-pretreated cells, phospho-β-
arrestin1 immunoreactivity was not increased in response to agonist;
in contrast, Ucn2 treatment signiﬁcantly reduced by 40% of basal
phospho-β-arrestin1 immunoreactivity within 5 min (Fig. 6a).
We further investigated whether changes in β-arrestin1 phos-
phorylation status affected its recruitment to the plasma membrane
and association with the receptor. Western blot analysis of 293-R2β
cell membrane fractions using β-arrestin1 speciﬁc antibodies showedn with CRH-R2β by ERK1/2. Inset: Validation of phospho β-arr1 (Se412) antibody.
branes, phospho-β-arr1 immunoreactivity was detected by using speciﬁc antibodies
hosphatase (ALP)-containing solution prior to detection of phospho- or total β-arr1
pre-treated with or without U0126 (10 μM) for 2 h before stimulation with Ucn2
phospho-β-arrestin1 (Ser412) were determined by speciﬁc antibodies and Alexa
). Alternatively (b), cell membrane-rich fractions were prepared and following SDS–
onjugated goat antirabbit IgG. (c) Identiﬁcation of β-arrestin and CRH-R2β complex
U0126 (10 μM) for 2 h before stimulation with Ucn2 (100 nM) for 2 min before
2 antibodies. Proteins were resolved on SDS–PAGE gels, followed by immunoblotting
or CRH-R1/2 (bottom panel) antibodies to identify potential complex formation.
endent experiments. Data represent the mean±SEM of two estimations from three
Dunnett's test to compare mean values between the treatment groups and controls
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plasma membrane was signiﬁcantly increased by 70–90% above basal
level, in agreement with previous studies [33]. This effect was
transient andwithin 10 min the rise in β-arrestin1membrane fraction
was reduced by 50% (Fig. 6b). Both basal and Ucn2 induced trafﬁcking
of β-arrestin1 appeared to be regulated by ERK1/2 since inhibition of
MEK and ERK1/2 by U0126 pretreatment signiﬁcantly increased (by
50%) basal β-arrestin1 recruitment to the plasma membrane. In the
absence of active ERK1/2, Ucn2 treatment of U0126-pretreated cells
did not signiﬁcantly alter β-arrestin1 recruitment to the plasma
membrane and levels of membrane-bound β-arrestin1 remained
unchanged for the period tested (up to 10 min) (Fig. 6b).
Potential changes in dynamics of CRH-R2β:β-arrestin1 binary
complex formation and regulation by ERK1/2 were also evaluated. For
this purpose, 293-R2β cells were pre-treated with U0126 or vehicle,
before treatment with Ucn2 (100 nM) for 2 min. Plasma membrane
fractions were prepared and solubilized before CRH-R2β receptor
immunoprecipitation by a speciﬁc CRH-R1/2 antibody and β-arrestin
co-puriﬁed with CRH-R2β receptors was detected by immunoblotting
using β-arrestin1 speciﬁc antibodies. Results (Fig. 6c) showed that
ERK1/2 inhibition signiﬁcantly enhanced by 40–60% agonist-induced
β-arrestin1 interaction with the CRH-R2β.
To conﬁrm that the feedback mechanism involving ERK1/2-
mediated phosphorylation β-arrestin1 could also modulate CRH-
R2β signaling potency as a result of altered CRH-R2β internalization
rate, we investigated whether the Ucn2-induced cAMP and Akt
pathways are also sensitive to changes in ERK1/2 activity. Our results
(Fig. 7a) showed that inhibition of ERK1/2 activity by U01260
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Fig. 7. Effect of ERK1/2 inhibition on Ucn2-stimulated cAMP production and Akt
phosphorylation in 293-R2β cells. Cells were pretreated with U0126 (10 μM for 2 h)
prior to stimulation with various concentrations of Ucn2 (0–100 nM) for 15 min (a) or
Ucn2 (100 nM) for 5 min (b). Cyclic AMP production was determined by ELISA and
Akt phosphorylation by immunoblotting using speciﬁc antibodies. Results are
expressed as % of maximal response (obtained with 100 nM Ucn2) and data represent
the mean±SEM of two estimations from three independent experiments. Data
analysis was carried out by using one-way ANOVA and Dunnett's test to compare
mean values between the treatment groups and controls (i.e., cells without U0126
pretreatment; *Pb0.05).signiﬁcantly reduced (by 40%) Ucn2 (1–100 nM)-induced, but not
basal, cAMP production. In contrast, agonist activated Akt phosphor-
ylation was not affected by inhibition of intracellular Erk1/2 activity
(Fig. 7b).
4. Discussion
It now well-established that cAMP and MAPK pathways play
prominent roles in mediating the physiological actions of CRH and
CRH-related peptides in most target tissues [1]. There are numerous
physiological paradigms where these two pathways interact to
coordinate their activity and inﬂuence the ﬁnal biological outcome.
For example, CRH activation of the CRH-R1/cAMP/PKA pathway in the
Ishikawa human endometrial adenocarcinoma and human breast
cancer MCF7 cell lines inhibits cell growth and proliferation possibly
by inhibiting MAPK activity [34,35]. Synergistic effects of the two
pathways have also been described in human mast cells where CRH
induces vascular endothelial growth factor release via the cAMP/PKA/
p38MAPK pathway [36] and the hippocampus, where cAMP-depen-
dent ERK1/2 activation is involved in the neuroprotective effects of
CRH and Ucn1 against excitotoxicity [37]. In the latter paradigm, PKA-
dependent ERK1/2 activation appears to be important for hippocam-
pal CRH-R2 mediated regulation of stress and fear memory responses
[13].
In this study, we provide novel insights into the mechanisms
regulating CRH-R2β signaling involving intracellular “cross-talk”
between cAMP and MAPK. Using a receptor over-expression system,
we demonstrated presence of a complex signaling network required
for maximal activation of ERK1/2 in response to Ucn2 activation that
involves PI3-K as well as increases in cAMP levels and downstream
PKA/AKAP interactions. In addition to PKA, Epac appears to play a role
in cAMP-dependent ERK1/2 activation. Epac has been previously
implicated in CRH and Ucn1 activation of ERK1/2 [27–29] and is also
involved in other Secretin GPCRs such as the parathyroid hormone
(PTH) and calcitonin receptors mediated ERK1/2 activation in bone
and rat kidney cells, respectively [38,39]. The ability of 8-CPT-2′-O-
Me-cAMP (a selective activator of Epac) to enhance Ucn2 effects
without affecting basal ERK1/2 phosphorylation might suggest that
Epac acts synergistically with another signaling pathway, possibly
PKA, to augment ERK1/2 activation. Similar synergistic effects
between Epac and PKA signaling pathways have been described in
vascular smooth muscle cells and in the BON human endocrine cell
line [40,41].
The effects of the cAMP cascade appears to be speciﬁc for ERK1/2
since Ucn2-induced PKB/Akt activation appears to depend on a
distinct pathway activated downstream of PTX-sensitive G-proteins
such as Gi/o and PI3-K activity which is independent of cAMP and
PKA/AKAP or PKC activity. At present, the speciﬁc “cross-talk” points
between cAMP/PKA and ERK1/2 signaling interactions are not known;
it is possible that the CRH-R2β itself is a phosphorylation target of
PKA. Similar PKA–GPCR interactions regulating signaling efﬁciency
have been described before; for example, phosphorylation by PKA of
the β2-adrenergic receptor switches its coupling from Gs to Gi to
allow stimulation of the ERK1/2 signaling pathway [20]. Previous
studies have shown that the CRH-R1, which is highly homologous to
CRH-R2 especially in the intracellular loops (IC) and C-terminus, can
also be targeted by PKA. A single serine residue (Ser301) present in IC3
appears to be the main target of PKA phosphorylation; this signaling
event leads to attenuation of receptor/Gq-protein coupling and
ERK1/2 activation [21]. It is also possible that Ucn2-activated PKA
directly modulates the activity of intracellular molecules down-
stream of PI3-K important for ERK1/2, but not Akt, activation. In
FRTL5 and Caco-2 thyroid and adenocarcinoma cell lines, cAMP/PKA
increases Ras and PI3-K association [42,43], possibly through
phosphorylation of p85, which stabilizes the complex p110-p85.
Interestingly, the early phase (2 min) of Ucn2-induced ERK1/2
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observation might point towards the involvement of diverse
signaling mechanisms determining the temporal characteristics of
ERK1/2 activation. Alternatively, it is possible that PKA inhibition
alters (accelerates) the transient kinetics of ERK1/2 activation.
One of the signaling events downstream of Ucn2-induced PKA
activation is translocation of AKAP250 (gravin) to the plasma
membrane that leads to association with the CRH-R2β via a
mechanism that requires intact PKA activity, thus suggesting
involvement of PKA-phosphorylation events. This scaffolding protein
has been implicated in the mechanism of GPCR trafﬁcking [24] and
studies in other GPCRs suggest that AKAP250 maintains PKA in close
proximity to the receptor and acts as scaffold for various kinases and
phosphatases involved in receptor signaling modulation through
trafﬁcking. In line with these observations, our studies demonstrated
the potential of PKA to regulate (delay) CRH-R2β internalization rate,
a ﬁnding that might explain the diminished ERK1/2 activation in the
absence of active PKA or disrupted PKA–AKAP interactions. Interest-
ingly, not all CRH-R2β-driven signaling responses were susceptible to
PKA effects and increased rate of receptor internalization since the
Gi/o-dependent Akt response was not affected by inhibition of PKA
activity. Given that CRH-R1 coupling efﬁciency to Gαs and Gαq/11,
but not Gαi, is susceptible to receptor desensitization and endocy-
tosis [44], it is attractive to speculate that only CRH-R2β-mediated
ERK1/2, but not Akt, activation is dependent on G-protein pathways
sensitive to desensitization and receptor internalization. The phys-
iological signiﬁcance of this divergence in the regulation of signaling
potency is not known; however, it is attractive to speculate that the
dissociation of Akt regulation from the ERK1/2 and cAMP/PKA
cascades might confer CRH-R2β the ability to selectively control
independent biological outcomes. Although important actions of
Ucns in the heart, such as the ability to protect cardiac cells againstFig. 8. Schematic representation of the proposed “cross-talk” mechanism regulating CRH-R2
binding to its receptor leads to an increase in intracellular cAMP levels through activation of
PKA and Epac-dependent pathways as well as involvement of PI3-K pathways (1). Activa
activation of PKA induces AKAP250 translocation to the plasma membrane and association
through an AKAP-dependent mechanism potentially targeting the receptor and/or other sig
with the receptor and ultimately the rate of receptor endocytosis (4). Inhibition of either PK
interaction with CRH-R2β, accelerated receptor endocytosis and impaired cAMP signaling (hypoxia/reoxygenation-induced cell death, involve both Akt and
ERK1/2 pathways [45] other urocortin actions are mediated by Akt
but not cAMP or ERK1/2 activation; examples include the urocortin
anti-inﬂammatory effects in cultured microglia that are PI3-K/Akt-
but not cAMP pathway-dependent and the urocortin-induced
inhibition of Beclin1 expression and autophagy as well as hypertro-
phy in cardiac myocytes mediated by activation of the PI3-K/Akt
pathway but which does not involve activation of ERK1/2 [46–48].
Moreover, our data suggest that PKA becomes an important
regulator of CRH-R2β internalization rate only in agonist-occupied
receptor since inhibition of activation of PKA does not affect CRH-R2β
trafﬁcking at basal state. This might suggest the requirement for
additional signaling molecules or mechanisms activated by Ucn2;
ERK1/2 might be such a candidate molecule since our results showed
that inhibition of ERK1/2 activity accelerates agonist-induced CRH-
R2β endocytosis. Our studies suggest that β-arrestin1 might be one of
ERK1/2 downstream targets involved in regulation of CRH-R2β
endocytosis. It has been shown that β-arrestin1 phosphorylation
and function aremodulated by an ERK1/2-dependentmechanism that
leads to attenuation of GPCRs internalization through negative
feedback [25] since dephosphorylated β-arrestin1 at the plasma
membrane is required for targeting agonist-occupied receptors to the
clathrin-coated pits. Our studies suggest that Ucn2 dependent ERK1/2
activation, although β-arrestin independent [17], can potentially
modulate β-arrestin1 phosphorylation and membrane translocation,
binary complex formation with CRH-R2β and ultimately CRH-R2β
endocytosis rate, in an autologous negative feedback mechanism.
Experimental conditions that diminish ERK1/2 activity result in
increased accumulation of β-arrestin1 to the plasma membrane,
thus allowing increased association with CRH-R2β and rate of
receptor endocytosis. The precise nature of the molecular determi-
nants regulating β-arrestin1 dephoshorylation are unknown;β signaling and endocytosis in HEK293 cells. According to this model (left panel), Ucn2
the Gs-adenylyl cyclase (AC) pathway and increased ERK1/2 phosphorylation through
tion of PI3-K by Gi/o pathways leads also to PKB/Akt phosphorylation. Downstream
with CRH-R2β (2). Moreover, PKA potentiates Ucn2-induced -ERK1/2, activation (3),
naling molecules. Activated ERK1/2 also regulates β-arrestin1 translocation, interaction
A activity, PKA–AKAP interactions or ERK1/2 activation results in increased β-arrestin1
right panel). In contrast, Akt activation is insensitive to PKA or ERK1/2 inhibition.
906 D. Markovic et al. / Biochimica et Biophysica Acta 1813 (2011) 896–907previous studies have shown that protein phosphatase 2A (PP2A) is
found in a molecular complex with β-arrestin1 and phosphatase
inhibitors increase Ser-412 phosphorylation [33]. Thus it is possible
that PP2A, through induction of β-arrestin1 dephosphorylation,
directly modulates β-arrestin1 interaction with clathrin and ulti-
mately receptor endocytosis. Evidence from other GPCR systems
suggests that in this signaling assembly of GPCR/β-arrestin1, PP2A is
capable of targetingmultiple substrates including the receptor protein
itself [49]. Interestingly, β-arrestin2 can also act as a signaling
intermediate through an Akt/PP2A scaffold that can mediate inacti-
vation of Akt in response to GPCR stimulation [50].
In conclusion, Ucn2 binding to CRH-R2β activates cAMP and ERK1/2
signaling cascades that interact throughPKA-mediatedphosphorylation
events and AKAPs to regulate ERK1/2 signal intensity and rate of
receptor endocytosis (Fig. 8). This mechanism induces AKAP250
translocation to the plasma membrane and interaction with the
receptor. Furthermore, this interaction exhibits signaling selectivity
since it does not appear to be important for activation of Akt, a
mechanism that is mediated via Gi/o-dependent pathways involving
PI3-K. ERK1/2 appears to regulate CRH-R2β endocytosis via direct
phosphorylation of β-arrestin1 in an auto-regulatory mechanism that
inﬂuences rate and extent of β-arrestin1 recruitment to the plasma
membrane and interaction with CRH-R2β.Acknowledgments
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